STOCK TITAN

Galecto (GLTO) director converts Series C preferred into 129,000 common shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Galecto, Inc. director Bruno Julianne reported acquiring Common Stock through the conversion of preferred shares. On February 9, 2026, after stockholders approved the issuance of Common Stock upon conversion of Series C Non-Voting Convertible Preferred Stock, 129 shares of Series C Preferred Stock converted into 129,000 shares of Common Stock at a price of $0 per share.

After this derivative conversion, Julianne directly beneficially owned 137,032 shares of Common Stock. These securities, including the newly issued Common Stock, are subject to a lock-up agreement related to Galecto’s public offering, restricting sales or transfers for 60 days following the February 10, 2026 final prospectus supplement.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bruno Julianne

(Last) (First) (Middle)
C/O GALECTO, INC.,
75 STATE STREET, SUITE 100

(Street)
BOSTON MA 02109

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Galecto, Inc. [ GLTO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/09/2026 M(1)(2) 129,000 A $0 137,032 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series C Preferred Stock (3) 02/09/2026 M(1)(2) 129 (3) (3) Common Stock 129,000 $0 0 D
Explanation of Responses:
1. On February 9, 2026, the Issuer's stockholders approved the issuance of Common Stock upon conversion of the Issuer's Series C Non-Voting Convertible Preferred Stock, par value $0.00001 per share ("Series C Preferred Stock") (the "Requisite Stockholder Approval"). Accordingly, pursuant to the terms of the Certificate of Designations of Preferences, Rights and Limitations of Series C Non-Voting Convertible Preferred Stock, 129 shares of Series C Preferred Stock held by the Reporting Person were converted into 129,000 shares of Common Stock. The securities of the Issuer held by the Reporting Person, including the shares of Common Stock received upon conversion of the Series C Preferred Stock, are subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 60 days
2. (Continued from footnote 1) following the date of the final prospectus supplement relating to the public offering, which was February 10, 2026.
3. Following receipt of the Requisite Stockholder Approval, each share of Series C Preferred Stock automatically converted into 1,000 shares of Common Stock, subject to certain beneficial ownership limitations. The Series C Preferred Stock has no expiration date.
/s/ Lori Firmani, attorney-in-fact 02/12/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Galecto (GLTO) director Bruno Julianne report?

Bruno Julianne reported a derivative conversion, not an open-market trade. On February 9, 2026, 129 shares of Series C Preferred Stock converted into 129,000 shares of Galecto Common Stock at $0 per share, increasing his directly held Common Stock position.

How many Galecto (GLTO) common shares did the director receive from the preferred conversion?

The director received 129,000 shares of Galecto Common Stock. These shares came from converting 129 shares of Series C Non-Voting Convertible Preferred Stock, reflecting a 1,000-to-1 conversion ratio following stockholder approval of the Common Stock issuance upon conversion.

What is Bruno Julianne’s Galecto (GLTO) common share ownership after this Form 4 transaction?

After the reported transaction, Bruno Julianne directly beneficially owned 137,032 shares of Galecto Common Stock. This total includes the 129,000 shares issued upon conversion of his Series C Preferred Stock into Common Stock at a zero-dollar exercise price.

Did Galecto (GLTO) shareholders approve the preferred-to-common stock conversion?

Yes. On February 9, 2026, Galecto stockholders approved issuing Common Stock upon conversion of the Series C Non-Voting Convertible Preferred Stock. Following this approval, each Series C share automatically converted into 1,000 Common shares, subject to stated beneficial ownership limitations.

Is the Galecto (GLTO) director restricted from selling the newly converted shares?

Yes. The director’s Galecto securities, including the converted Common Stock, are subject to a lock-up agreement. He agreed, with certain exceptions, not to directly or indirectly sell or transfer issuer securities for 60 days after the February 10, 2026 final prospectus supplement.

What are the key terms of Galecto’s Series C Preferred Stock noted in this Form 4?

Each Series C Preferred share converts into 1,000 Galecto Common shares after receipt of the required stockholder approval. The Series C Preferred Stock has no expiration date, and its conversion is subject to specified beneficial ownership limitations described in the certificate of designations.
Galecto Inc.

NASDAQ:GLTO

GLTO Rankings

GLTO Latest News

GLTO Latest SEC Filings

GLTO Stock Data

34.88M
841.27k
3.68%
12.25%
0.95%
Biotechnology
Pharmaceutical Preparations
Link
Denmark
BOSTON